US consumers continue to buy potentially risky drugs over Internet, FDA study finds

8 July 2007

New data collected by the US Food and Drug Administration show that consumers who are trying to save money on prescription drugs do not need to take chances by buying their medicines from foreign Internet sites, because low-cost generic versions are available in the USA. This finding also may be an indication that some consumers are likely buying foreign drugs this way to avoid getting a prescription from their doctor or health care professional, since many web sites do not require a prescription.

Safety concerns

The use of prescription drugs without a prescription is an intrinsically unsafe practice and the FDA urges consumers to have one from their doctor or other health care professional before using such medicines. The agency also urges consumers to review its web site, www.fda.gov for important information before making purchases.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight